GENinCode Plc, a cardiovascular disease company, focuses on predictive genetics for the prevention of cardiovascular disease. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company‘s invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. It operates business in Europe and Latin America. The company was incorporated in 2018 and is based in Oxford, the United Kingdom.